1 Challenges in the clinical utility of the serum test for HER2 ECD
来源:BBA-REV CANCER( P 0304-419X E 1879-2561 ) 发表时间: 2012/08
类型:期刊论文 为本人加分:2980.495119
2 FOXP3 and Its Cofactors as Targets of Immunotherapies
来源:ENGINEERING-PRC( P 2095-8099 E 2096-0026 ) 发表时间: 2019/02
类型:期刊论文 为本人加分:693.756518
3 A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector..
来源:ONCOIMMUNOLOGY( P 2162-402X E ) 发表时间: 2018/01
类型:期刊论文 为本人加分:436.536054
4 Monitoring serum HER2 levels in breast cancer patients
来源:SPRINGERPLUS( P 2193-1801 E ) 发表时间: 2015/05
类型:期刊论文 为本人加分:405.743281
5 scFv-Based "Grababody" as a General Strategy to Improve Recruitment of Immune Effector Cel..
来源:CANCER RES( P 0008-5472 E 1538-7445 ) 发表时间: 2013/04
类型:期刊论文 为本人加分:19.092599
6 Rational Design of Constrained Peptides as Protein Interface Inhibitors
来源:ANTIBODIES( P E 2073-4468 ) 发表时间: 2021/09
类型:期刊论文 为本人加分:6.069219